Literature DB >> 11060326

Vascular endothelial growth factor as a target for antiangiogenic therapy.

M S Gordon1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11060326

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  3 in total

1.  Phase I study of pre-operative continuous 5-FU and sorafenib with external radiation therapy in locally advanced rectal adenocarcinoma.

Authors:  Richard Kim; Gopi Kesaria Prithviraj; Ravi Shridhar; Sarah E Hoffe; Kun Jiang; Xiuhua Zhao; Dung-Tsa Chen; Khaldoun Almhanna; Jonathan Strosberg; Tiffany Campos; David Shibata
Journal:  Radiother Oncol       Date:  2016-02-06       Impact factor: 6.280

2.  Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis.

Authors:  Byung Woog Kang; Tae Won Kim; Jae-Lyun Lee; Min-Hee Ryu; Heung Moon Chang; Chang Sik Yu; Jin Cheon Kim; Jong Hoon Kim; Yoon-Koo Kang; Jung Shin Lee
Journal:  Med Oncol       Date:  2008-05-22       Impact factor: 3.064

Review 3.  In pursuit of new anti-angiogenic therapies for cancer treatment.

Authors:  Jun Cai; Song Han; Ruan Qing; Daiqing Liao; Brian Law; Michael E Boulton
Journal:  Front Biosci (Landmark Ed)       Date:  2011-01-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.